Weight loss outcomes associated with semaglutide treatment for patients with overweight or obesity, JAMA Network Open (2022) Metabolic adaptations to weight loss: A brief review, The Journal of Strength and Conditioning Research (2022) Semaglutide for the treatment of overweight and obesity: A review, Diabetes, Obesity, and Metabolism (2022) Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension, Diabetes, Obesity and Metabolism (2022) A comprehensive review on weight gain following discontinuation of glucagon-like peptide-1 receptor agonists for obesity, Journal of Obesity (2024) Weight maintenance on cost-effective antiobesity medications after 1 year of GLP-1 receptor agonist therapy: A real-world study, Obesity (2024) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice
Bundle pricing makes sense if you are committed to the treatment timeline
Take the Assessment Retatrutide: Phase 3 (TRIUMPH program)
Red flags that warrant immediate medical attention include suicidal thoughts, severe mood changes within days of starting or increasing the dose, withdrawal from social activities, or loss of interest in activities you normally enjoy
First, reduced efficacy may lead to inadequate blood glucose control in patients with type 2 diabetes, potentially resulting in hyperglycemia and increased risk of diabetic complications
The hard part is ditching the excuses and the perfectionist mentality (ahem, guilty as charged) and doing the best you can